However, in the context of other recent studies demonstrating the therapeutic potential of Ang‐1 agonists in influenza pneumonia (Sugiyama et al., 2015), the current work with Ang‐2 antagonism helps build enthusiasm for developing therapeutics targeting this pathway in viral pneumonia, including COVID‐19. This evidence concerns the gene ANGPT2 and COVID-19.